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3 months was attained by 35.6% (379 patients). Prior statin 
use was not associated with increased odds for sICH (OR 1.05, 
95% CI 0.55–2.04, p = 0.864), mortality (OR 1.32, 95% CI 0.90–
1.93, p = 0.152) or favourable outcome (OR 0.89, 95% CI 0.65–
1.24, p = 0.507). Similar results were found for the different 
lipid variables: high LDL (OR 0.96, 95% CI 0.36–2.60, p = 
0.942), high triglyceride (OR 1.74, 95% CI 0.84–3.56, p = 0.132) 
and low HDL (OR 1.78, 95% CI 0.68–4.65, p = 0.279) were not 
associated with increased odds for sICH. Likewise, neither 
mortality nor functional outcome at 3 months was sig-
nificantly associated with any of the lipid variables in the 
 univariable analysis following Bonferroni adjustment for 
multiple comparisons. The same results were found in the 
multivariable analysis adjusting for imbalances in baseline 
characteristics.  Conclusions: In contrast to previous studies, 
we found that in stroke patients receiving thrombolysis ther-
apy, neither the lipid profile nor prior statin use were associ-
ated with increased odds for sICH, functional outcome or 
mortality at 3 months.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Intracerebral haemorrhage (ICH) is one of the most 
feared complications after thrombolytic therapy in stroke 
patients. Depending on the definition, it occurs in ap-
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 Abstract 
 Background: It is unclear if a certain lipid profile and/or 
statin use contribute to symptomatic intracerebral haemor-
rhage (sICH), poor outcome or mortality after intravenous 
thrombolysis for ischaemic stroke. The aim of the current 
study was to assess the impact of statin use and lipid profile 
on sICH, outcome and mortality following thrombolysis in 
acute stroke.  Methods: From 2001 to 2010, all patients ad-
mitted to our hospital and undergoing intravenous throm-
bolysis for acute ischaemic stroke were included into an 
open, prospective database. Initial stroke severity was as-
sessed using the National Institute of Health Stroke Scale. 
Demographics, vascular risk factors, admission blood pres-
sure, glucose levels, previous medication including statin 
use, lipid profiles including low-density lipoprotein (LDL), 
high-density lipoprotein (HDL) and triglyceride levels were 
recorded. Outcome measures included sICH according to 
the European Cooperative Acute Stroke Study II criteria, 
modified Rankin scale and mortality at 3 months.  Results: 
1,066 patients were included in the analysis; 5.3% (57 pa-
tients) had sICH. Mortality at 3 months was 17.6% (188 pa-
tients). A favourable outcome (modified Rankin scale 0–1) at 
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proximately 6% of patients and is associated with a poor 
outcome  [1] . Different factors, such as the presence of ear-
ly hypodensity on CT, elevated serum glucose, history of 
diabetes, increased time to treatment, higher pre-treat-
ment blood pressure, lower platelet count and history of 
cardiac disease, have been suggested as predictors of ICH 
after thrombolysis  [2] .
 However, the role of the lipid profile and prior statin 
use for the occurrence of symptomatic ICH (sICH) fol-
lowing intravenous thrombolysis and their implications 
for the outcome remain unclear. While the protective
role of hydroxymethylglutaryl-CoA reductase inhibitors 
(statins) in first-ever and recurrent ischaemic strokes is 
clearly proven  [3] , some authors also report statin use to 
be associated with favourable functional outcome follow-
ing thrombolysis  [4] , and others identified statin medica-
tion and low low-density lipoprotein (LDL) as risk factors 
for thrombolysis-related haemorrhages  [5, 6] . However, 
the data remain controversial as some studies only identi-
fied high-admission triglyceride levels as a risk factor for 
sICH, but not LDL levels or statin therapy  [7] . Finally, 
other authors report that the use of statins or hypercho-
lesterolaemia before first-ever ischaemic stroke is associ-
ated with a better early outcome, while statin therapy may 
increase the risk of ICH  [8] .
 The present study aims to investigate the role of the 
lipid profile and statin use prior to intravenous thrombo-
lytic therapy for acute ischaemic stroke patients in the 
occurrence of sICH based on our local thrombolysis da-
tabase including 1,066 patients, employing two different 
definitions of ICH. Furthermore, the impact on function-
al outcome and mortality was assessed.
 Methods 
 Patients 
 From 2001 to 2010 (cut-off point of the current analysis: 19 No-
vember 2010), all patients admitted to our hospital and undergoing 
intravenous thrombolysis for acute ischaemic stroke were included 
into an open, prospective database. Initial stroke severity was as-
sessed using the National Institute of Health Stroke Scale (NIHSS) 
by a trained neurologist. Demographics, vascular risk factors, ad-
mission blood pressure, glucose levels, and previous medication 
including statin use were recorded. Lipid profiles were assessed as 
fasting values the morning following admission, including LDL, 
high-density lipoprotein (HDL), LDL/HDL ratio and triglyceride 
levels. Patients underwent a non-contrast brain CT scan before 
treatment and a routine brain CT scan 24–36 h after thrombolysis. 
Stroke subtypes were classified according to the TOAST classifica-
tion: (1) large-artery atherosclerosis, (2) cardioembolism, (3) 
small-artery occlusion (lacunar), (4) stroke of other determined 
aetiology, and (5) stroke of undetermined aetiology  [9] .
 Outcome Parameters 
 Outcome parameters included the occurrence of sICH within 
36 h following thrombolysis, the occurrence of any ICH, mortal-
ity at 3 months and functional outcome at 3 months. sICH was 
assessed using the slightly modified European Cooperative Acute 
Stroke Study (ECASS II) criteria (any haemorrhage with neuro-
logical deterioration, as indicated by an NIHSS score  6 4 points 
higher than the value at baseline, or any haemorrhage leading to 
death). Any ICH was defined as any blood on the follow-up CT 
scan within 36 h following thrombolysis. Functional outcome was 
assessed upon discharge and in the 90 days of follow-up and was 
measured by the modified Rankin scale (mRS) score. Favourable 
outcome was defined as an mRS score of 0–1.
 Statistical Analysis 
 Baseline variables were compared using Pearson’s   2 and the 
Mann-Whitney U tests where appropriate. For categorical vari-
ables, percentage proportions were calculated by dividing the 
number of events by the total number of patients, excluding miss-
ing or unknown cases. Analogously, median and interquartile 
ranges were calculated for continuous variables, leaving out miss-
ing or unknown cases.
 Based on the literature  [3–7] , low LDL levels, low HDL levels, 
high triglyceride levels and a high LDL/HDL ratio were consid-
ered risk factors for sICH, mortality and outcome. For further 
analyses, the population was thus grouped according to (1) statin 
use, (2) high versus low LDL levels, (3) high versus low HDL levels, 
(4) high versus low triglyceride levels, and (5) high versus low 
LDL/HDL ratio. For LDL, the cut-off of 100 mg/dl was chosen ac-
cording to current guidelines  [10] . Since no thresholds for HDL, 
triglycerides and the LDL/HDL ratio have been reported in the 
literature, the population was split using the 25th (for HDL) and 
75th (for triglycerides and LDL/HDL ratio) percentiles as cut-off 
values. Odds ratios were calculated using 2  ! 2 cross-tables. Ad-
justed odds ratios were calculated using logistic regression models 
including age, gender, baseline NIHSS, hypertension, diabetes, 
atrial fibrillation, systolic and diastolic blood pressure, glucose 
level on admission, and stroke aetiology. All statistical analyses 
were performed using the SPSS software (version 16.0). Following 
Bonferroni adjustment for multiple comparisons, only p values 
 ! 0.01 were considered significant.
 Results 
 In total, 1,066 patients were registered in our local 
thrombolysis database. Baseline characteristics are listed 
in  table 1 .
 sICH according to ECASS II criteria occurred in 57 
patients (5.3%), while any ICH on the post-treatment CT 
scan was found in 186 patients (17.4%). Overall mortality 
at 3 months was 17.6% (188 patients). A favourable out-
come (mRS 0–1) at 3 months was reached by 379 patients 
(35.6%). The number of patients with prior statin medica-
tion were equally distributed in patients with or without 
haemorrhages ( table 1 ). Likewise, there was no significant 
difference in median LDL, HDL or triglyceride levels and 
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the LDL/HDL ratio between patients with or without 
ICH, regardless of the definition ( table 1 ).
 According to the literature, prior statin use, low LDL, 
low HDL and high triglyceride levels, as well as a high 
LDL/HDL ratio were defined as risk factors for sICH, 
mortality or unfavourable outcome. So far, no definite 
thresholds have been published. Therefore, in an explor-
atory approach, we defined low or high values according 
to the 25th and 75th percentiles in our population.
 Prior statin use was not associated with significantly 
increased odds for sICH according to ECASS II (OR 1.05, 
95% CI 0.55–2.04, p = 0.864), any ICH (OR 1.35, 95% CI 
0.92–1.96, p = 0.122), mortality (OR 1.32, 95% CI 0.90–
1.93, p = 0.152) or decreased odds for favourable outcome 
(OR 0.89, 95% CI 0.65–1.24, p = 0.507;  table 2 ).
 Similar results were found for all lipid variables in-
cluding low LDL ( ^  100 mg/dl), low HDL ( ^  36 mg/dl), 
high triglycerides ( 6 144 mg/dl) and high LDL/HDL ra-
tios ( 6 3.33) ( table 2 ). Of note, the Bonferroni adjustment 
was applied to correct for multiple comparisons, and 
thus, only p values  ! 0.01 were considered significant.
 Table 3 shows the multivariate analysis. As in the uni-
variate analysis, after adjustment for baseline characteris-
tics, neither prior statin use nor any of the lipid variables 
were associated with significantly increased odds for sICH, 
mortality or decreased odds for favourable functional out-
come at 3 months. Although LDL levels below the 25th 
percentile were associated with a slightly increased risk of 
mortality (OR 1.82, 95% CI 1.01–3.29, p = 0.047), the result 
was not considered significant applying Bonferroni adjust-
ment for multiple comparisons, requiring a p value  ! 0.01.
 Discussion 
 Based on our local thrombolysis database including a 
total of 1,066 patients, we found neither previous statin 
therapy nor the lipid profile to be associated with the oc-
Table 1.  Baseline characteristics
Total
(n = 1,066)
sICH Any ICH
yes (n = 57) no (n = 1,009) p yes (n = 1 86) no (n = 880) p
Categorical variables
Male sex 563/1,066 (52.8) 22/57 (38.6) 541/1,009 (53.6) 0.0272 86/186 (46.2) 477/880 (54.2) 0.0481
Hypertension 832/1,063 (78.3) 51/57 (89.5) 781/1,006 (77.6) 0.0352 152/186 (81.7) 680/877 (77.5) 0.2091
Diabetes 276/1,063 (26.0) 22/57 (38.6) 254/1,005 (25.3) 0.0262 57/186 (30.6) 219/876 (25.0) 0.1111
Atrial fibrillation 354/1,064 (33.3) 24/57 (42.1) 330/1,007 (32.8) 0.1462 80/186 (43.0) 274/878 (31.2) 0.0021
Statin 209/1,018 (20.5) 12/57 (21.4) 197/962 (20.5) 0.8642 45/182 (24.7) 144/836 (19.6) 0.1221
TOAST
Large-artery atherosclerosis 206/1,066 (19.3) 4/57 (7.0) 202/1,009 (20.0) 23/186 (12.4) 183/880 (20.8)
Cardioembolism 547/1,066 (51.3) 36/57 (63.2) 511/1,009 (50.6) 123/186 (66.1) 424/880 (48.2)
Small-artery occlusion 44/1,066 (4.1) 0/57 (0) 44/1,009 (4.4) 0.0402 1/186 (0.5) 43/880 (4.9) <0.0011
Other 31/1,066 (2.9) 1/57 (1.8) 30/1,009 (3.0) 4/186 (2.2) 27/880 (3.1)
Unknown 238/1,066 (22.3) 16/57 (28.1) 222/1,009 (22.0) 35/186 (18.8) 203/880 (23.1)
Continuous variables
Age 73 [15]/1,066 73 [10]/57 73 [15]/1,009 0.9561 74 [12]/186 73 [15]/880 0.2202
Baseline NIHSS 12 [10]/1,065 15 [9]/57 12 [10]/1,008 0.0411 15 [9]/186 11 [9]/879 <0.0012
LDL 115 [48]/662 114 [64]/18 115 [48]/644 0.9811 110 [47]/97 116 [47]/565 0.0792
HDL 44 [16]/670 39 [21.3]/18 44 [17]/652 0.0811 44 [17]/98 44 [17]/572 0.4002
Triglycerides 103 [69]/885 101 [83]/33 103 [69]/852 0.7051 95 [61]/146 104 [71]/739 0.0702
LDL/HDL 2.7 [1.3]/662 3.0 [1.1]/18 2.6 [1.3]/644 0.0651 2.5 [1.3]/97 2.7 [1.3]/565 0.5612
Systolic BP 160 [31]/859 150 [30]/45 160 [31]/814 0.4291 157 [28]/160 160 [31]/699 0.0822
Diastolic BP 87 [17]/855 84 [18]/44 87 [17]/811 0.2101 86 [22]/159 87 [16]/696 0.6782
Glucose 122 [44]/1,062 132 [48]/57 121 [43]/1,005 0.1061 125 [47]/186 121 [43]/876 0.0192
Dat a for categorical variables are number of patients/number of patients with data available for the specific category, with percentages in 
parentheses. For continuous variables, data are the median [with interquartile ranges in brackets]/number of patients with data available for 
the specific category. TOAST = Trial of Org 10172 in Acute Stroke Treatment; BP = blood pressure. sICH according to ECASS II criteria.
1 2 test. 2 Mann-Whitney U test.
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currence of thrombolysis-related ICH as described in 
previous studies  [5–7, 11–13] , regardless of the definition 
used for ICH. The same was found for mortality or func-
tional outcome at 3 months.
 These findings are in contrast to previous studies, 
which report concerning results about lipid profiles and 
statin use as risk factors for thrombolysis-related ICH (for 
an overview, see  table 4 ).
 Bang et al.  [6] analyzed 104 patients receiving intrave-
nous or intra-arterial thrombolysis with tissue plasmino-
gen activator (tPA), including mechanical recanalization. 
In their study, lower LDL cholesterol levels upon admis-
sion but not prior statin use were found to be indepen-
dently associated with sICH. In contrast, Uyttenboogaart 
et al.  [7] including a population of 252 patients treated 
with intravenous tPA for acute ischaemic stroke only 
identified high triglyceride levels but not low LDL or pri-
or statin as risk factors for sICH. Two other studies fi-
nally reported the use of lipid-lowering medication as an 
 independent risk factor for sICH following thrombolysis 
 [5, 12] .
 In contrast to these studies – and in line with our re-
sults – the report of Montaner  [14] showed a lack of as-
sociation between previous statin use or the lipid profile 
with sICH among recombinant tPA-treated patients. 
However, the sample size was relatively small, including 
only lipid profiles – in contrast to other studies assessed 
in the hyperacute phase – from 60 patients; the results on 
prior statin use were based on 145 patients. Furthermore, 
a recent case-control study including 182 patients showed 
no significant difference in the incidence of sICH in pa-
tients with versus in those without statin pre-treatment 
(3.3 vs. 1.7%; p = 0.47)  [15] . Likewise, there was no differ-
ence between the two groups with respect to favourable 
short-term (44.8 vs. 56%; p = 0.31) or long-term outcome 
(40 vs. 44.1%; p = 0.84). In contrast, in a meta-analysis 
provided in the same paper including 1,055 patients, 
statin pre-treatment was neither related to long-term 
functional outcome nor to mortality, but was shown to be 
a risk factor for sICH (OR 1.99, 95% CI 1.03–3.84, p = 
0.04)  [15] .
 The heterogeneity in the previous studies may be due 
to several reasons. Firstly, they included a heterogeneous 
population undergoing different treatment modalities, 
including mechanical recanalization  [6] and intra-arteri-
al urokinase  [5] . Second, all studies except for one  [7] in-
vestigated only partial aspects, for instance providing 
data on statin use  [8, 12] but not reporting lipid profiles, 
or providing data on sICH but not on functional out-
comes  [6, 8] . Furthermore, sample sizes in most of these Ta
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Table 3.  Adjusted ORs for the different outcome parameters
sICH Any ICH Mortality1 O utcome (mRS 0 –1)1
OR p OR p OR p OR p
Statin 1.18 (0.56–2.48) 0.669 1.21 (0.79–1.8) 0.379 1.32 (0.82–2.10) 0.249 1.14 (0.76–1.73) 0.525
LDL ≤100 mg/dl 0.77 (0.26–2.24) 0.625 1.21 (0.75–1.96) 0.429 1.12 (0.68–1.99) 0.576 0.99 (0.65–1.53) 0.971
HDL ≤25th 1.85 (0.64–5.37) 0.257 1.27 (0.75–2.13) 0.370 1.82 (1.01–3.29) 0.047 0.74 (0.45–1.17) 0.200
Triglycerides ≥75th 1.69 (0.77–3.73) 0.192 0.83 (0.52–1.32) 0.434 1.33 (0.78–2.26) 0.293 1.19 (0.79–1.77) 0.500
Ratio ≥75th 1.75 (0.62–5.04) 0.289 0.99 (0.57–1.69) 0.969 1.29 (0.70–2.38) 0.421 0.74 (0.46–1.81) 0.206
ORs are adj usted for age, sex, baseline NIHSS, hypertension, diabetes, atrial fibrillation, systolic and diastolic blood pressure, glu-
cose, and TOAST criteria using a logistic regression model. Figures in parentheses are 95% CIs. Only p values <0.01 were considered 
significant according to Bonferroni adjustment for multiple comparisons.
1 Three months after discharge.
Table 4.  Overview of selected previous studies on the association between lipid profiles and sICH and outcome
Reference Cohort/
treatment
Variables sICH rate, % sICH definition Independent
risk for sICH
Outcome
Bang
et al. [6], 2007 
104 patients
IV or IA rtPA,
mechanical or
combined
total cholesterol,
LDL, HDL and
triglycerides
16.3 any clinical worsening
associated with HT in
CT scan
1. NIHSS 
2. low LDL
3. current smoking
not reported
Montaner [14],
20081
60 patients
(lipid profiles)
145 patients
(statin use)
IV rtPA
total cholesterol,
LDL, HDL and
triglycerides
8.3 (of 60 patients
with lipid profiles);
8.3 (statins) versus
9.3 (no statins)
not reported lipid profile and 
statins not associated 
with sICH;
predictors for sICH 
not reported
not reported (for lipid 
profile), statin use 
predictor for good 
functional outcome
Uyttenboogard
et al. [7], 2008 
252 patients
IV rtPA
total cholesterol,
LDL, HDL and
triglycerides
5.2 neurological deteriora-
tion within 48 h follow-
ing rtPA treatment with 
HT in CT scan
1. serum glucose
2. NIHSS
3. anti-platelets
4. high triglycerides
lipid profile and statins 
not associated with 
favourable outcome at 
3 months
Tsivgoulis
et al. [12], 2009 
510 patients
IV rtPA
lipid-lowering
medication before
rtPA treatment;
lipid profile not
reported
6.1 brain imaging evidence
of ICH and clinical
worsening of NIHSS
scale ≥4
1. BP protocol 
violation
2. NIHSS
3. lipid-lowering
medication
not reported
Meier
et al. [5], 2009 
311 patients 
IA urokinase
total cholesterol,
LDL, HDL and
triglycerides
4.8 PH2 with clinical
worsening of NIHSS
scale ≥4
1. prior statin use
2. NIHSS
3. atrial fibrillation
4. worse collaterals
lipid profile and statins 
not associated with 
clinical outcome at 
3 months
Miedema
et al. [13], 2010 
476 patients
IV rtPA
total cholesterol
and LDL
5.8 SITS-MOST criteria not reported lipid profile not 
associated with 
favourable outcome
Martinez-Ramirez
et al. [15], 2011 
182 patients
IV rtPA
statin use before
stroke, hyper-
cholesterolaemia
2.2 SITS-MOST criteria not reported no differences between 
prior statin use and no 
statin use regarding 
sICH or outcome
I V = Intravenous; IA = intra-arterial; HT = haemorrhagic transformation; BP = blood pressure; PH2 = parenchymal haemorrhage type 2; SITS-
MOST = Safe Implementation of Thrombolysis in Stroke-Monitoring Study.
1 Lipids were measured in the hyperacute phase of stroke (<3 h)
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studies were relatively small, ranging between 60 and 510 
patients ( table 4 ), resulting in wide 95% CIs. Unfortunate-
ly, the by far largest registry of thrombolytic therapy in 
stroke patients (SITS-ISTR) did not collect information 
about statin pre-treatment or cholesterol subgroups up to 
2011. Thus, for an analysis of the influence of the lipid 
profile and lipid-lowering drugs, single or oligo-centre 
registries have to be used.
 Furthermore, with respect to sICH, the influence of 
the sICH definition has to be taken into account, since 
frequencies and risk factors may vary widely depending 
on the definition used  [16] . In our study, lipid profiles or 
statin therapy were not associated with thrombolysis-re-
lated ICH, regardless of the definition used.
 Our study included the so far largest population, pro-
viding data on lipid profiles, statin pre-treatment and dif-
ferent outcome parameters, but nevertheless has some 
limitations. Firstly, although the lipid profile was per-
formed in a 12- to 24-hour fasting status, lipid levels in 
the acute phase of stroke may decrease. However, we 
aimed to determine the relation between admission lipid 
levels and prior statin use in acute thrombolyzed patients. 
Secondly, the retrospective character of our study and the 
non-blinded follow-up data collection could lead to a pos-
sible bias. Especially, since lipid profiles were not avail-
able for the entire population (LDL for 62.1%, HDL 62.9% 
and triglyceride 83.0%) and the baseline characteristics 
between those with versus those without LDL levels avail-
able differed significantly (see online suppl. table 1, www.
karger.com/doi/10.1159/000335840). However, data on 
statin use were available for 95.5% of the population. Fi-
nally, data on pre-stroke mRS were not available, which 
may bias our outcome analysis since 17.9% of our patients 
had a history of previous stroke.
 In summary, in contrast to previous studies, neither 
prior statin use nor the lipid profile were associated with 
sICH or any of the outcome parameters in patients un-
dergoing thrombolysis for acute ischaemic stroke. An on-
going multi-centric, randomized, double-blind clinical 
trial now aims to evaluate the use of simvastatin in the 
acute phase of ischaemic stroke with respect to function-
al outcome and its association to haemorrhagic transfor-
mation  [17] . This trial may help give a final answer to the 
question of statin use in patients undergoing thromboly-
sis for acute stroke.
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